These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats. Breese GR; Napier TC; Mueller RA J Pharmacol Exp Ther; 1985 Aug; 234(2):447-55. PubMed ID: 3926987 [TBL] [Abstract][Full Text] [Related]
25. Parametric and pharmacological analyses of the enhanced grooming response elicited by the D1 dopamine receptor agonist SKF 38393 in the rat. Wachtel SR; Brooderson RJ; White FJ Psychopharmacology (Berl); 1992; 109(1-2):41-8. PubMed ID: 1365670 [TBL] [Abstract][Full Text] [Related]
26. Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors? White FJ; Bednarz LM; Wachtel SR; Hjorth S; Brooderson RJ Pharmacol Biochem Behav; 1988 May; 30(1):189-93. PubMed ID: 2902644 [TBL] [Abstract][Full Text] [Related]
27. Sniffing, rearing and locomotor responses to the D-1 dopamine agonist R-SK&F 38393 and to apomorphine: differential interactions with the selective D-1 and D-2 antagonists SCH 23390 and metoclopramide. Molloy AG; Waddington JL Eur J Pharmacol; 1985 Feb; 108(3):305-8. PubMed ID: 3886407 [TBL] [Abstract][Full Text] [Related]
28. Locomotor effects of amantadine in the mouse are not those of a typical glutamate antagonist. Starr MS; Starr BS J Neural Transm Park Dis Dement Sect; 1995; 9(1):31-43. PubMed ID: 7605588 [TBL] [Abstract][Full Text] [Related]
29. Downregulation of stereotyped behavior and production of latent locomotor behaviors in mice treated continuously with quinpirole. Zhou LW; Qin ZH; Weiss B Neuropsychopharmacology; 1991 Jan; 4(1):47-55. PubMed ID: 1672250 [TBL] [Abstract][Full Text] [Related]
30. Effects of selective drugs for dopaminergic D1 and D2 receptors on conditioned locomotion in rats. Mazurski EJ; Beninger RJ Psychopharmacology (Berl); 1991; 105(1):107-12. PubMed ID: 1684056 [TBL] [Abstract][Full Text] [Related]
31. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767 [TBL] [Abstract][Full Text] [Related]
32. Combination of a delta opioid receptor agonist but not a mu opioid receptor agonist with the D1-selective dopamine receptor agonist SKF 38393 markedly potentiates different behaviors in mice. Toyoshi T; Ukai M; Kameyama T Eur J Pharmacol; 1992 Mar; 213(1):25-30. PubMed ID: 1354161 [TBL] [Abstract][Full Text] [Related]
33. Dynorphin A(1-13) preferentially inhibits behaviors induced by the D2 dopamine agonist RU 24213 but not by the D1 dopamine agonist SK&F 38393. Ukai M; Toyoshi T; Kameyama T Pharmacol Biochem Behav; 1992 Aug; 42(4):755-9. PubMed ID: 1355296 [TBL] [Abstract][Full Text] [Related]
34. Motor depression: a new role for D1 receptors? Chandler CJ; Wohab W; Starr BS; Starr MS Neuroscience; 1990; 38(2):437-45. PubMed ID: 2148204 [TBL] [Abstract][Full Text] [Related]
35. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity. Lublin H; Gerlach J; Peacock L Psychopharmacology (Berl); 1993; 112(2-3):389-97. PubMed ID: 7871047 [TBL] [Abstract][Full Text] [Related]
36. Evidence that the stimulus properties of apomorphine are mediated by both D1 and D2 receptor activation. Schechter MD; Greer NL Life Sci; 1987 Jun; 40(25):2461-71. PubMed ID: 2953944 [TBL] [Abstract][Full Text] [Related]
37. Concomitant D1 dopamine receptor activation (SKF 38393) unmasks D2 dopaminergic actions of B-HT 920 in mice. Verma A; Kulkarni SK Indian J Exp Biol; 1991 Feb; 29(2):123-6. PubMed ID: 1831182 [TBL] [Abstract][Full Text] [Related]
38. Polydipsia and dopamine: behavioral effects of dopamine D1 and D2 receptor agonists and antagonists. Mittleman G; Rosner AL; Schaub CL J Pharmacol Exp Ther; 1994 Nov; 271(2):638-50. PubMed ID: 7965779 [TBL] [Abstract][Full Text] [Related]
39. Selective protection from the inhibition by EEDQ of D1 and D2 dopamine agonist-induced rotational behavior in mice. Goodale DB; Jacobi AG; Seyfried DM; Weiss B Pharmacol Biochem Behav; 1988 Jun; 30(2):457-62. PubMed ID: 2902647 [TBL] [Abstract][Full Text] [Related]
40. Individual differences in behavior following amphetamine, GBR-12909, or apomorphine but not SKF-38393 or quinpirole. Hooks MS; Jones DN; Holtzman SG; Juncos JL; Kalivas PW; Justice JB Psychopharmacology (Berl); 1994 Oct; 116(2):217-25. PubMed ID: 7862951 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]